Ozempic Timeline and Early Use
Ozempic (semaglutide) was approved by the U.S. Food and Drug Administration in 2017 for type 2 diabetes. By 2019–2020, clinicians and patients began using it off-label for weight management, especially after clinical data showed significant body-weight reductions.
Why Ozempic Became Popular for Weight Loss
Media coverage of supply shortages and celebrity use accelerated interest in 2021–2022. Social media, patient forums, and news reports highlighted rapid weight-loss results, driving demand. Clinical trials of semaglutide for obesity, published in 2021, further supported its use and broadened awareness.
Current Context and Availability
By 2023, Ozempic remained in high demand, with shortages reported by pharmacies and health systems. In June 2023, the FDA approved a higher-dose version of semaglutide specifically for weight loss under the brand Wegovy. For background on its diabetes approval, see the FDA label information at https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637.
